Vanda Pharmaceuticals (NASDAQ: VNDA) boosts 2026 revenue view on new approvals
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Vanda Pharmaceuticals reported Q1 2026 net product sales of $51.7 million, a 3% increase from Q1 2025, driven by 26% Fanapt® sales growth to $29.6 million. HETLIOZ® sales fell to $15.9 million, while PONVORY® rose to $6.2 million.
The company posted a net loss of $48.6 million (diluted loss per share $0.82), wider than the prior-year loss, reflecting higher selling, general and administrative spending and investments in launches and pipeline programs. Cash, cash equivalents and marketable securities totaled $202.3 million as of March 31, 2026.
Vanda raised its full-year 2026 revenue guidance to $240–$290 million, including $10–$30 million expected from newly launched NEREUS™. The quarter also featured FDA approval of BYSANTI™ (milsaperidone) for bipolar I disorder and schizophrenia and FDA acceptance of a BLA for imsidolimab in Generalized Pustular Psoriasis with a PDUFA target action date of December 12, 2026.
Positive
- Raised 2026 revenue outlook: Full-year 2026 total revenue guidance increased from $230–$260 million to $240–$290 million, including $10–$30 million expected from newly launched NEREUS™.
- Major product approvals and pipeline progress: BYSANTI™ (milsaperidone) received FDA approval for bipolar I disorder and schizophrenia, and the imsidolimab BLA for Generalized Pustular Psoriasis was accepted with a December 12, 2026 PDUFA target action date.
Negative
- Widening losses despite higher revenue: Net loss grew to $48.6 million in Q1 2026 from $29.5 million in Q1 2025, reflecting significantly higher operating expenses tied to launches and pipeline investment.
Insights
New product approvals, a key BLA milestone and higher 2026 guidance offset modest top-line growth and a wider loss.
Vanda Pharmaceuticals delivered Q1 2026 revenue of $51.7 million, up 3% year over year, with strong Fanapt® growth of 26% to $29.6 million. HETLIOZ® declined to $15.9 million, while PONVORY® rose to $6.2 million, showing mixed product dynamics.
Profitability weakened, as net loss expanded to $48.6 million with diluted loss per share of $0.82, versus $29.5 million a year earlier. Higher selling, general and administrative expenses and launch investments weighed on results, while cash, cash equivalents and marketable securities of $202.3 million as of March 31, 2026 provide funding for ongoing programs.
Strategically, the company raised 2026 total revenue guidance to $240–$290 million, now including $10–$30 million from NEREUS™, and secured FDA approval of BYSANTI™ plus BLA acceptance for imsidolimab with a December 12, 2026 PDUFA date. These regulatory milestones and the expanded product portfolio could become important future revenue drivers, subject to successful commercialization and regulatory outcomes.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q1 2026 total net product sales: $51.7 million
Fanapt net product sales: $29.6 million
HETLIOZ net product sales: $15.9 million
+5 more
8 metrics
Q1 2026 total net product sales
$51.7 million
Net product sales in Q1 2026, up 3% vs Q1 2025
Fanapt net product sales
$29.6 million
Q1 2026, 26% year-over-year increase
HETLIOZ net product sales
$15.9 million
Q1 2026, down from $20.9 million in Q1 2025
PONVORY net product sales
$6.2 million
Q1 2026, 10% year-over-year increase
Q1 2026 net loss
$48.6 million
Net loss in Q1 2026 vs $29.5 million in Q1 2025
Cash, cash equivalents and marketable securities
$202.3 million
Balance as of March 31, 2026
2026 total revenue guidance (revised)
$240–$290 million
Updated full-year 2026 revenue range
NEREUS 2026 sales guidance
$10–$30 million
Expected NEREUS net product sales for full-year 2026
Key Terms
PDUFA target action date, Biologics License Application, data exclusivity, new-to-brand prescriptions (NBRx), +2 more
6 terms
PDUFA target action date regulatory
"PDUFA target action date of December 12, 2026"
The PDUFA target action date is the deadline set by the U.S. Food and Drug Administration (FDA) by which it aims to decide whether to approve or reject a new drug application. This date helps investors gauge when a company’s new medication might reach the market, potentially influencing sales and revenue expectations. It acts as a key milestone signaling progress in the drug approval process.
Biologics License Application regulatory
"The FDA accepted the Biologics License Application (BLA) for imsidolimab"
A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.
data exclusivity regulatory
"is protected by data exclusivity through February 20, 2031"
new-to-brand prescriptions (NBRx) financial
"new-to-brand prescriptions (NBRx)1 up 76% versus Q1 2025"
Generalized Pustular Psoriasis medical
"Imsidolimab BLA for Generalized Pustular Psoriasis accepted for FDA review"
A rare, severe form of psoriasis that causes sudden, widespread patches of pus-filled bumps, intense redness and peeling skin, often with fever and other body-wide symptoms; it can require hospitalization and can be life-threatening. Investors should care because the condition drives demand for specialized therapies, influences clinical trial urgency and regulatory attention, and can affect market size and pricing potential for drugs targeting this high-need patient group—like a small but high-impact niche in healthcare.
social anxiety disorder medical
"Phase III study of VQW-765 in the treatment of adults with social anxiety disorder"
Social anxiety disorder is a mental health condition characterized by a strong fear of social situations where one might be judged or embarrassed. This fear can lead individuals to avoid social interactions, which may impact their personal and professional lives. For investors, understanding this condition is important because it can influence decision-making, communication, and overall well-being in the workplace.
Earnings Snapshot
Total net product sales: $51.7 million · Guidance included
Q1 2026
Total net product sales
$51.7 million
+3% YoY
Net loss
$48.6 million
Fanapt net product sales
$29.6 million
+26% YoY
HETLIOZ net product sales
$15.9 million
Guidance
Full-year 2026 total revenues now expected between $240 million and $290 million, including $10–$30 million from NEREUS net product sales.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 6, 2026
(Exact name of Registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File No.) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (202 ) 734-3400
| Not Applicable | ||
| (Former Name or Former Address, if Changed Since Last Report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02. | Results of Operations and Financial Condition. | |||||||
On May 6, 2026, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended March 31, 2026 (the “Earnings Call”). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Various statements to be made during the Earnings Call are “forward-looking statements” under the securities laws, including, but not limited to, statements regarding Vanda’s commercial products, plans and opportunities, as well as statements about Vanda’s products in development and the related clinical development and regulatory timelines and commercial potential for such products. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “project,” “target,” “goal,” “likely,” “will,” “would,” and “could,” or the negative of these terms and similar expressions or words, identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties.
Important factors that could cause actual results to differ materially from those reflected in Vanda’s forward-looking statements include, among others, Vanda’s assumptions regarding the strength of its business in the U.S. and Vanda’s ability to complete the clinical development of, and obtain regulatory approval for, the products in its pipeline. Therefore, no assurance can be given that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements made during the Earnings Call should be evaluated together with the various risks and uncertainties that affect Vanda’s business and market, particularly those identified in the “Cautionary Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s most recent Annual Report on Form 10-K, as updated by Vanda’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. The information contained in this Current Report on Form 8-K is intended to be considered in the context of Vanda’s filings with the SEC and other public announcements that Vanda makes, by press release or otherwise, from time to time. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information conveyed on the Earnings Call will be provided only as of the date thereof, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements made during the Earnings Call after the date thereof, whether as a result of new information, future events or otherwise, except as required by law.
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. | |||||||
(d)Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press release of Vanda Pharmaceuticals Inc. dated May 6, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: | May 6, 2026 | VANDA PHARMACEUTICALS INC. | |||||||||||||||
| By: | /s/ Kevin Moran | ||||||||||||||||
| Name: | Kevin Moran | ||||||||||||||||
| Title: | Senior Vice President, Chief Financial Officer and Treasurer | ||||||||||||||||
Exhibit 99.1
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
•Fanapt® net product sales rose 26% to $29.6 million; total prescriptions increased 32% and new-to-brand prescriptions surged 76%
•NEREUSTM (tradipitant) launched via nereus.us, an innovative direct-to-consumer platform – the first new prescription medicine in more than 40 years for the prevention of vomiting induced by motion, with convenient online ordering and rapid direct home delivery
•Full-year 2026 revenue guidance raised to $240-$290 million, including $10-30 million from newly launched NEREUSTM
•BYSANTITM (milsaperidone) received FDA approval for bipolar I disorder and schizophrenia on February 20, 2026
•Imsidolimab BLA for Generalized Pustular Psoriasis accepted for FDA review; PDUFA target action date of December 12, 2026
WASHINGTON – May 6, 2026 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2026.
“Vanda delivered strong commercial execution in the first quarter, highlighted by 26% growth in Fanapt sales, the groundbreaking U.S. launch of NEREUS with its pioneering direct-to-consumer platform at nereus.us, and the FDA approval of BYSANTI,” said Mihael H. Polymeropoulos, M.D., Vanda’s President, CEO and Chairman of the Board. “We believe that these achievements, combined with meaningful pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.”
Financial Highlights
•Total net product sales reached $51.7 million in Q1 2026, a 3% increase compared to $50.0 million in Q1 2025.
•Fanapt® net product sales were $29.6 million, up 26% year-over-year.
•HETLIOZ® net product sales were $15.9 million, down 24% year-over-year.
•PONVORY® net product sales were $6.2 million, up 10% year-over-year.
•Loss before income taxes was $48.4 million compared with $37.4 million in Q1 2025, reflecting continued investment in new product launches and pipeline advancement.
•Cash, cash equivalents and marketable securities (Cash) totaled $202.3 million as of March 31, 2026, representing a decrease to Cash of $61.5 million in Q1 2026, which included a one-time payment of a $10.0 million milestone to Eli Lilly due upon approval of NEREUS™ (tradipitant).
Key Commercial Highlights
•Fanapt® saw continued strong momentum with total prescriptions (TRx)1 up 32% and new-to-brand prescriptions (NBRx)1 up 76% versus Q1 2025. In April 2026, weekly TRx for Fanapt® reached an 11-year high of over 2,600 prescriptions for the week ending April 24, 2026.
•NEREUSTM is now commercially available nationwide through nereus.us, Vanda’s innovative direct-to-consumer platform. This pioneering patient-centric model enables convenient ordering online with rapid direct delivery, eliminating traditional pharmacy barriers and providing a seamless, modern access experience. As the first new prescription therapy approved for the prevention of vomiting induced by motion in adults in more than 40 years, NEREUSTM represents a breakthrough in both science and patient access.
Key Regulatory & Clinical Development Highlights
•BYSANTITM (milsaperidone) received U.S. Food and Drug Administration (FDA) approval for the treatment of bipolar I disorder and schizophrenia. BYSANTITM is protected by data exclusivity through February 20, 2031 and multiple patents, the latest of which expires on May 31, 2044.
•Vanda’s ongoing late-stage clinical studies are progressing rapidly and are expected to generate topline results in 2026 or early 2027, including:
◦The Phase III study of BYSANTITM as a once-daily adjunctive treatment for major depressive disorder (MDD), with results expected in Q1 2027.
◦The Thetis Phase III study of NEREUS™ for the prevention of vomiting in patients receiving GLP-1 receptor agonist therapies, with results expected in 2026.
◦The Phase III study of VQW-765 in the treatment of adults with social anxiety disorder, with results expected by the end of 2026.
•The FDA accepted the Biologics License Application (BLA) for imsidolimab in Generalized Pustular Psoriasis (GPP) with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026. The results of the pivotal clinical study were published in the April 28, 2026 issue of the New England Journal of Medicine (NEJM) Evidence2.
Corporate Highlight
•On April 22, 2026, Vanda appointed Charles Duncan, Ph.D. to its Board of Directors. The Board now consists of seven directors, six of whom are independent.
GAAP Financial Results
Net loss was $48.6 million (diluted loss per share of $0.82) in Q1 2026 compared with a net loss of $29.5 million (diluted loss per share of $0.50) in Q1 2025.
2026 Financial Guidance
Vanda is raising its full-year 2026 total revenue guidance to reflect the contribution of the newly launched NEREUS™ while maintaining prior ranges for Fanapt® and other products:
Full Year 2026 Financial Objectives | Prior Full Year 2026 Guidance | Revised Full Year 2026 Guidance | ||||||
| Total revenues | $230 to $260 million | $240 to $290 million | ||||||
Fanapt® net product sales | $150 to $170 million | $150 to $170 million | ||||||
NEREUSTM net product sales | Not provided | $10 to $30 million | ||||||
| Other net product sales | $80 to $90 million | $80 to $90 million | ||||||
Conference Call
Vanda has scheduled a conference call for today, Wednesday, May 6, 2026, at 4:30 PM ET. During the call, Vanda’s management will discuss the first quarter 2026 financial results and other corporate activities. Investors can call 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode number 8051722. A replay of the call will be available on Wednesday, May 6, 2026, beginning at 8:30 PM ET and will be accessible until Wednesday, May 13, 2026 at 11:59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 8051722.
The conference call will be broadcast simultaneously on Vanda’s website, www.vandapharma.com. Investors should click on the Investors tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda’s website for a period of 30 days.
References
1.IQVIA Prescription Data
2.Smieszek, S. et al. Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis. NEJM Evidence 5, (2026).
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Various statements in this press release, including, but not limited to, the guidance provided under “2026 Financial Guidance” above and statements regarding Vanda’s plans for pursuit of FDA approval of imsidolimab for the treatment of GPP, and the related timeline for approval; Vanda’s expectations with respect to its continued growth and ability to create value; Vanda’s clinical development plans and expected timelines for BYSANTITM for the treatment of MDD, NEREUSTM in the prevention of vomiting induced by GLP-1 therapies, and VQW-765 in the treatment of adults with social anxiety disorder; and Vanda’s expectations with respect to the strength of its business are “forward-looking statements” under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda’s forward-looking statements include, among others, Vanda’s ability to continue to grow its business; the FDA’s ability to complete its review of, and reach a decision with respect to, the BLA for imsidolimab by December 12, 2026; Vanda’s ability to successfully execute the commercial launches of NEREUSTM for the prevention of vomiting induced by motion and BYSANTI™ for the treatments of bipolar I disorder and schizophrenia; Vanda’s ability to continue to advance its late-stage clinical development programs and to obtain regulatory approval for, and successfully commercialize, the late-stage products in development; Vanda’s ability to complete the clinical study for BYSANTITM for the treatment of MDD and receive results in in the first quarter of 2027; Vanda’s ability to complete the Thetis study and receive results in 2026; and Vanda’s ability to complete the clinical study for VQW-765 in the treatment of adults with social anxiety disorder and receive results by the end of 2026. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda’s business and market, particularly those identified in the “Cautionary Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s most recent Annual Report on Form 10-K, as updated by Vanda’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except for share and per share amounts)
(unaudited)
| Three Months Ended | |||||||||||
| March 31 2026 | March 31 2025 | ||||||||||
| Revenues: | |||||||||||
Fanapt® net product sales | $ | 29,560 | $ | 23,545 | |||||||
HETLIOZ® net product sales | 15,947 | 20,872 | |||||||||
PONVORY® net product sales | 6,211 | 5,624 | |||||||||
| Total revenues | 51,718 | 50,041 | |||||||||
| Operating expenses: | |||||||||||
| Cost of goods sold excluding amortization | 3,159 | 3,521 | |||||||||
| Research and development | 28,435 | 35,712 | |||||||||
| Selling, general and administrative | 68,361 | 50,084 | |||||||||
| Intangible asset amortization | 1,987 | 1,752 | |||||||||
| Total operating expenses | 101,942 | 91,069 | |||||||||
| Loss from operations | (50,224) | (41,028) | |||||||||
| Other income, net | 1,800 | 3,660 | |||||||||
| Loss before income taxes | (48,424) | (37,368) | |||||||||
| Provision (benefit) for income taxes | 143 | (7,874) | |||||||||
Net loss | $ | (48,567) | $ | (29,494) | |||||||
Net loss per share, basic | $ | (0.82) | $ | (0.50) | |||||||
| Net loss per share, diluted | $ | (0.82) | $ | (0.50) | |||||||
Weighted average shares outstanding, basic | 59,459,982 | 58,527,775 | |||||||||
| Weighted average shares outstanding, diluted | 59,459,982 | 58,527,775 | |||||||||
VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
| March 31 2026 | December 31 2025 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 54,034 | $ | 84,851 | |||||||
| Marketable securities | 148,276 | 178,996 | |||||||||
| Accounts receivable, net | 56,879 | 54,578 | |||||||||
| Inventory | 1,699 | 1,852 | |||||||||
| Prepaid expenses and other current assets | 32,281 | 26,985 | |||||||||
| Total current assets | 293,169 | 347,262 | |||||||||
| Property and equipment, net | 2,245 | 2,248 | |||||||||
| Operating lease right-of-use assets | 4,536 | 3,923 | |||||||||
| Finance lease right-of-use assets | 7,284 | 7,343 | |||||||||
| Intangible assets, net | 115,102 | 117,089 | |||||||||
| Non-current inventory and other | 11,189 | 11,083 | |||||||||
| Total assets | $ | 433,525 | $ | 488,948 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable and accrued liabilities | $ | 60,620 | $ | 68,297 | |||||||
| Product revenue allowances | 74,962 | 76,865 | |||||||||
| Total current liabilities | 135,582 | 145,162 | |||||||||
| Operating lease non-current liabilities | 3,266 | 2,991 | |||||||||
| Finance lease non-current liabilities | 3,785 | 4,076 | |||||||||
| Other non-current liabilities | 10,127 | 9,533 | |||||||||
| Total liabilities | 152,760 | 161,762 | |||||||||
| Stockholders’ equity: | |||||||||||
| Common stock | 60 | 59 | |||||||||
| Additional paid-in capital | 723,826 | 721,264 | |||||||||
| Accumulated other comprehensive income | 212 | 629 | |||||||||
| Accumulated deficit | (443,333) | (394,766) | |||||||||
| Total stockholders’ equity | 280,765 | 327,186 | |||||||||
| Total liabilities and stockholders’ equity | $ | 433,525 | $ | 488,948 | |||||||
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
Follow us on X @vandapharma
FAQ
How did Vanda Pharmaceuticals (VNDA) perform financially in Q1 2026?
Vanda reported Q1 2026 net product sales of $51.7 million, a 3% increase from $50.0 million in Q1 2025. Net loss widened to $48.6 million, or $0.82 per diluted share, compared with a $29.5 million net loss, or $0.50 per share, a year earlier.
What were the key product trends for Vanda Pharmaceuticals (VNDA) in Q1 2026?
Fanapt® net product sales rose 26% year over year to $29.6 million, showing strong momentum. HETLIOZ® net product sales declined to $15.9 million, while PONVORY® increased to $6.2 million. These shifts highlight a growing contribution from Fanapt® and PONVORY®.
Did Vanda Pharmaceuticals (VNDA) change its 2026 revenue guidance?
Yes. Vanda raised full-year 2026 total revenue guidance from $230–$260 million to $240–$290 million. The updated outlook now includes projected NEREUS™ net product sales of $10–$30 million, while guidance for Fanapt® and other products remains unchanged.
What recent FDA milestones has Vanda Pharmaceuticals (VNDA) achieved?
Vanda received FDA approval for BYSANTI™ (milsaperidone) to treat bipolar I disorder and schizophrenia. The FDA also accepted a Biologics License Application for imsidolimab in Generalized Pustular Psoriasis, assigning a PDUFA target action date of December 12, 2026.
What is Vanda Pharmaceuticals’ (VNDA) cash position after Q1 2026?
As of March 31, 2026, Vanda held $202.3 million in cash, cash equivalents and marketable securities. This reflects a $61.5 million decrease during Q1 2026, which included a $10.0 million milestone payment to Eli Lilly triggered by NEREUS™ approval.
How significant was Fanapt® prescription growth for Vanda Pharmaceuticals (VNDA)?
Fanapt® showed strong demand, with total prescriptions up 32% and new-to-brand prescriptions up 76% versus Q1 2025. In April 2026, weekly total prescriptions reached an 11-year high of over 2,600 for the week ending April 24, underscoring growing utilization.